Targeted therapy with trastuzumab in dysplasia and adenocarcinoma arising in Barrett's esophagus: A translational approach

Minerva Gastroenterologica e Dietologica

Volumn 54, Issue 4, 2008, Pages 347-353

  Villanacci, V ^a,c   Rossi, E ^a   Grisanti, S ^a   Bassotti, G ^b   Ferrari, V D ^a   Missale, G ^a   Minelli, L ^a   Cengia, P ^a   Marini, G ^a   Cestari, R ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c 2nd Department of Pathology   (Italy)

Author keywords

Adenocarcinoma; Barrett esophagus; Trastuzumab

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTON PUMP INHIBITOR; SINGLE STRANDED DNA; TRASTUZUMAB;

AGED; APOPTOSIS; ARTICLE; BARRETT ESOPHAGUS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOVASCULAR DISEASE; CASE REPORT; DOWN REGULATION; DRUG TARGETING; DRUG TOLERANCE; DYSPLASIA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGOSCOPY; ESOPHAGUS MUCOSA; ESOPHAGUS SURGERY; FEASIBILITY STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE AMPLIFICATION; GENE OVEREXPRESSION; HEART LEFT VENTRICLE EJECTION FRACTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; RECEPTOR DOWN REGULATION; SIDE EFFECT;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BARRETT ESOPHAGUS; ESOPHAGEAL NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; RECEPTOR, ERBB-2;

EID: 59749102436     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Fitzgerald RC. Molecular basis of Barrett's oesophagus and oesophageal adenocarcinoma. Gut 2006;55:1810-20.
2. Tselepis C, Perry I, Jankowski J. Barrett's esophagus: disregulation of cell cycling and intercellular adhesion in the metaplasia-dysplasia-carcinoma sequence. Digestion 2000;6:1-5.
3. Jankowski J, Hopwood D, Wormsley KG Expression of epidermal growth factor, transforming growth factor alpha and their receptor in gastro-oesophageal diseases. Dig Dis 1993;11:1-11.
4. Hardwick RH, Barham CP, Ozua P, Newcomb PV, Savage P, Powell R et al. Immunohistochemical detection of p53 and c-erbB-2 in oesophageal carcinoma; no correlation with prognosis. Eur J Surg Oncol 1997;23:30-5.
5. Friess H, Fukuda A, Tang WH, Eichenberger A, Furlan N, Zimmermann A et al. Concomitant analysis of the epidermal growth factor receptor family in esophageal cancer: overexpression of epidermal growth factor receptor mRNA but not of c-erbB-2 and c-erbB-3. World J Surg 1999;23:1010-8.
6. Geddert H, Zeriouh M, Wolter M, Heise JW, Gabbert HE, Sarbia M. Gene amplification and protein overexpression of c-erb-b2 in Barrett carcinoma and its precursor lesions. Am J Clin Pathol 2002;118:60-6.
7. Sharma P, Dent J, Armstrong D, Bergman JJ, Gossner L, Hoshihara Y et al. The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria. Gastroenterology 2006;131:1392-9.
8. Hamilton SR, Aaltonen LA. WHO Pathology and genet ics: Tumors of digestive system. Lyon: IARC Press; 2000.
9. Sato S, Kajiyama Y, Sugano M, Iwanuma Y, Sonoue H, Matsumoto T et al. Monoclonal antibody to HER-2/neu receptor enhances radiosensitivity of esophageal cancer cell lines expressing HER-2/neu oncoprotein. Int J Radiat Oncol Biol Phys 2005;61:203-11.
10. Safran H, DiPetrillo T, Nadeem A, Steinhoff M, Tantravahi U, Rathore R et al. Trastuzumab, paclitaxel, cisplatin, and radiation for adenocarcinoma of the esophagus: a phase I study. Cancer Invest 2004;22:670-7.
11. Safran H, Dipetrillo T, Akerman P, Ng T, Evans D, Steinhoff M et al. Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma. Int J Radiat Oncol Biol Phys 2007;67:405-9.
12. Baselga J, Carbonell X, Castañeda-Soto NJ, Clemens M, Green M, Harvey V et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005;23:2162-71.
13. Järvinen TA, Tanner M, Bärlund M, Borg A, Isola J. Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes Chromosomes Cancer 1999;26:142-50.
14. Xiao H, Li TK, Yang JM, Liu LF. Acidic pH induces topoisomerase II-mediated DNA damage. Proc Natl Acad Sci U S A 2003;100:5205-10.